Related Experiment Video

Updated: Dec 10, 2025

Detection and Isolation of Apoptotic Bodies to High Purity
12:17

Detection and Isolation of Apoptotic Bodies to High Purity

Published on: August 12, 2018

11.2K

Unleashing the therapeutic potential of apoptotic bodies

Thanh Kha Phan1, Dilara Ceyda Ozkocak1, Ivan Ka Ho Poon1

  • 1Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria 3086, Australia.

Biochemical Society Transactions
|September 2, 2020
PubMed

Insights

Apoptotic bodies (ApoBDs), a type of extracellular vesicle (EV), show therapeutic promise. This review explores strategies, advantages, and challenges for developing ApoBD-based therapies, positioning them for future EV-based treatments.

Area of Science:

  • Cell biology
  • Biotechnology
  • Therapeutics

Background:

  • Extracellular vesicles (EVs) are cell-released vesicles with therapeutic and diagnostic potential.
  • Exosomes and microvesicles are well-studied EVs used as drug delivery platforms and for biomarker discovery.
  • Apoptotic bodies (ApoBDs), a distinct EV type from apoptotic cells, have largely unexplored therapeutic applications.

Purpose of the Study:

  • To review strategies for developing ApoBD-based therapies.
  • To highlight the advantages and challenges associated with ApoBD therapeutics.
  • To position ApoBDs as a promising area within EV-based therapy.

Main Methods:

  • Literature review of recent studies on ApoBD biogenesis and function.
  • Analysis of therapeutic strategies for ApoBD development.
  • Discussion of the potential and limitations of ApoBD-based treatments.

Main Results:

  • ApoBDs are implicated in therapeutic potential due to their unique biogenesis and functions.
  • Various strategies for developing ApoBD-based therapies are being explored.
  • Key advantages and challenges in ApoBD therapeutic development have been identified.

Conclusions:

  • ApoBDs represent a largely untapped resource for novel EV-based therapies.
  • Further research into ApoBD biogenesis and function can unlock their full therapeutic potential.
  • ApoBDs are positioned as a promising frontier in the field of extracellular vesicle therapeutics.
Keywords:
apoptosisapoptotic bodiesextracellular vesiclestherapeutics

More Related Videos

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death09:18

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Published on: December 27, 2016

9.0K
Experimental Analysis of Apoptotic Thymocyte Engulfment by Macrophages06:47

Experimental Analysis of Apoptotic Thymocyte Engulfment by Macrophages

Published on: May 24, 2019

7.5K

Related Concept Videos

Phagocytosis of Apoptotic Cells01:17

Phagocytosis of Apoptotic Cells

Cells undergoing apoptosis form apoptotic bodies that must be removed immediately to prevent inflammation, autoimmune diseases, and necrosis. Phagocytosis is carried out by professional phagocytes such as macrophages or  immature dendritic cells. Non-professional phagocytes such as  epithelial cells and fibroblasts also take part in this process; however, they are not as effective as professional phagocytes. 
Normal cells contain receptors that prevent them from being recognized...
4.5K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
7.6K
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size...
13.3K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.8K
Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
8.8K
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
4.0K